Spero Therapeutics, Inc. (SPRO)

Spero Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 22, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	138	56	78	90	518	527
Market Cap Growth	130.05%	-27.92%	-13.02%	-82.69%	-1.83%	186.63%
Enterprise Value	89	-16	-10	46	401	408
Last Close Price	2.36	1.03	1.47	1.73	16.01	19.39
PE Ratio	-	-	3.42	-	-	-
PS Ratio	3.23	1.17	0.75	1.67	28.35	56.50
PB Ratio	5.02	1.22	0.73	1.18	5.86	3.99
P/TBV Ratio	5.06	1.22	0.73	1.18	5.86	3.99
EV/Sales Ratio	2.19	-	-	0.86	21.98	43.73
Debt / Equity Ratio	0.13	0.09	0.05	0.09	0.63	0.06
Debt / EBITDA Ratio	-	-	0.19	-	-	-
Asset Turnover	0.43	0.33	0.68	0.36	0.11	0.07
Quick Ratio	3.74	2.15	3.42	5.09	7.98	9.28
Current Ratio	3.83	2.19	3.53	5.25	8.46	9.70
Return on Equity (ROE)	-95.30%	-89.62%	24.95%	-56.53%	-81.47%	-75.77%
Return on Assets (ROA)	-29.77%	-30.93%	10.90%	-12.91%	-33.88%	-38.10%
Return on Invested Capital (ROIC)	-56.38%	-55.63%	17.17%	-16.86%	-38.73%	-44.95%
Return on Capital Employed (ROCE)	-111.30%	-117.90%	18.40%	-29.60%	-57.70%	-56.90%
Earnings Yield	-32.69%	-122.10%	29.27%	-51.82%	-17.34%	-14.85%
FCF Yield	-20.64%	-41.75%	-42.35%	-8.63%	-12.43%	-16.32%
Buyback Yield / Dilution	-2.96%	-1.98%	-40.98%	-21.65%	-38.01%	-23.27%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q